Page last updated: 2024-10-19

niacinamide and Depression

niacinamide has been researched along with Depression in 30 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research Excerpts

ExcerptRelevanceReference
"Depression is the leading cause of mental health-related disease globally, and it affects an estimated 300 million people worldwide."5.51Antidepressant activity of crocin-I is associated with amelioration of neuroinflammation and attenuates oxidative damage induced by corticosterone in mice. ( Fu, Z; Shen, Q; Wang, L; Xiao, Q; Xie, X; Xiong, Z; Yu, C; Zhou, J, 2019)
" No previous study has, however, designated the time of TRP dosing to improve mood."2.90Effect of Tryptophan, Vitamin B ( Akamatsu, Y; Hayashi, T; Moritani, T; Nishida, MM; Tsujita, N, 2019)
"Depression is one of the most common psychiatric disorders, and there is strong demand for developing novel antidepressants with better efficacy and less adverse effects."1.62Antidepressant-like effects of 1-methylnicotinamide in a chronic unpredictable mild stress model of depression. ( Gu, JH; Ji, CH; Jiang, B; Liu, Y; Tang, WQ; Zhang, Y; Zhao, J, 2021)
"Depression is the leading cause of mental health-related disease globally, and it affects an estimated 300 million people worldwide."1.51Antidepressant activity of crocin-I is associated with amelioration of neuroinflammation and attenuates oxidative damage induced by corticosterone in mice. ( Fu, Z; Shen, Q; Wang, L; Xiao, Q; Xie, X; Xiong, Z; Yu, C; Zhou, J, 2019)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-199015 (50.00)18.7374
1990's0 (0.00)18.2507
2000's2 (6.67)29.6817
2010's8 (26.67)24.3611
2020's5 (16.67)2.80

Authors

AuthorsStudies
Wu, W1
Bours, MJL1
Koole, A1
Kenkhuis, MF1
Eussen, SJPM1
Breukink, SO1
van Schooten, FJ1
Weijenberg, MP1
Hageman, GJ1
Xiao, Q1
Xiong, Z1
Yu, C1
Zhou, J1
Shen, Q1
Wang, L1
Xie, X1
Fu, Z1
Jiang, Y1
Liu, Y2
Gao, M1
Xue, M1
Wang, Z1
Liang, H1
Tsujita, N1
Akamatsu, Y1
Nishida, MM1
Hayashi, T1
Moritani, T1
Liu, Z1
Li, C1
Fan, X1
Kuang, Y1
Zhang, X1
Chen, L1
Song, J1
Zhou, Y1
Takahashi, E1
He, G1
Li, W1
Zhao, J1
Zhang, Y1
Tang, WQ1
Ji, CH1
Gu, JH1
Jiang, B1
Willyard, C1
Bhattacharya, A1
Wang, Q1
Ao, H1
Shoblock, JR1
Lord, B1
Aluisio, L1
Fraser, I1
Nepomuceno, D1
Neff, RA1
Welty, N1
Lovenberg, TW1
Bonaventure, P1
Wickenden, AD1
Letavic, MA1
Gudkova, AN1
Osinovskaia, NA1
Polunina, AG1
Gekht, AB1
Belova, LA1
Mashin, VV1
Kolotik-Kameneva, OY1
Belova, NV1
Lethbridge, NL1
Chazot, PL1
Lepow, L1
Luckenbaugh, DA1
Park, L1
Henter, ID1
Zarate, CA1
Kats-Ugurlu, G1
Maass, C1
van Herpen, C1
de Waal, R1
Oosterwijk, E1
Mulders, P1
Hulsbergen-van de Kaa, C1
Leenders, W1
Rex, A1
Schickert, R1
Fink, H1
Chichakli, H1
Frosch, PJ1
Brinkmeier, T1
Young, SN5
Chouinard, G5
Annable, L5
Mys'ko, GN1
Fernando, JC1
Joseph, MH1
Curzon, G1
MacSweeney, DA1
Badawy, AA2
Evans, M2
Sourkes, TL4
Cazzullo, CL1
Sacchetti, E1
Smeraldi, E1
Kiriakos, RZ1
Stern, FH1
Schmitz, W1
Mangoni, A1
Green, RG1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nicotinamide Riboside in Ulcerative Colitis[NCT05561738]40 participants (Anticipated)Interventional2024-01-01Not yet recruiting
An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression[NCT00040261]Phase 3112 participants Interventional2002-06-30Completed
Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699]Phase 1/Phase 267 participants (Actual)Interventional2004-07-26Completed
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression[NCT00986479]Phase 222 participants (Actual)Interventional2009-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

MADRS Score - Baseline

Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Ketamine - Healthy Volunteers1.17
Placebo - Healthy Volunteers1.48
Ketamine - MDD Patients33.83
Placebo - MDD Patients31.82

MADRS Score - Day 1 Following Intervention

Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1

Interventionunits on a scale (Mean)
Ketamine - Healthy Volunteers2.45
Placebo - Healthy Volunteers0.67
Ketamine - MDD Patients23.73
Placebo - MDD Patients30.68

Beck Depression Inventory (BDI) Score.

Beck Depression Inventory (BDI) is a 21-question instrument for measuring the severity of depression. Each question has a set of at least four possible answer choices, ranging in intensity. A value of 0 to 3 is assigned for each answer and the total score is computed. Higher total scores indicate more severe depressive symptoms. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)21.08122.21721.53521.12622.44422.92323.49424.447
Placebo22.88623.12223.58623.68622.93624.58623.78624.070

Brief Psychiatric Rating Scale (BPRS) Positive Score.

Brief Psychiatric Rating Scale (BPRS) Positive is a 4-item scale which measures positive symptoms of schizophrenia (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content). Each item is rated from 1 to 7 with higher score indicating greater severity. The total score is the sum of the 4 items, resulting in a range of scores from 4-28. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)9.4338.7518.6608.7519.1149.1189.1189.356
Placebo8.9468.9968.9968.6669.2969.2969.4469.338

Brief Psychiatric Rating Scale (BPRS) Score.

"The Brief Psychiatric Rating Scale (BPRS) is a 18-item scale which measures symptoms and behaviors that are characteristic of schizophrenia. Each item is rated from 1 to 7 with higher score indicating greater severity. The total score is the sum of the 18 items, resulting in a range of scores from 18-126.~18 is considered to be the best outcome, 126 the worst." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)32.19130.23730.55530.73733.41832.88234.16835.739
Placebo32.89633.49633.69631.77233.59634.49633.04634.428

Clinician-Administered Dissociative States Scale (CADSS) Score.

Clinician- Administered Dissociative States Scale (CADSS) is a clinician-administered measure of perceptual, behavioral, and attentional alterations occurring during dissociative experiences. This scale involves a 23 questions and each is rated from 0 (not at all) to 4 (extremely). The total score is sum of the 23 items and range from 0 to 92 - best is 0 and worst is 92. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)4.1043.3242.8311.2401.0131.3601.4561.313
Placebo1.9972.2972.0471.4971.1471.3971.4471.212

Hamilton Anxiety Rating Scale (HAM-A) Total Score.

Hamilton Anxiety Rating Scale (HAM-A) is used as a rating measure of anxiety severity. The scale consists of 14 items. Each item is rated on a scale of 0 to 4. The HAM-A total score is the sum of the 14 items and the score ranges from 0 to 56. 0 is considered the best outcome, 56 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionUnits on a scale (Least Squares Mean)
230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)16.21116.66616.81717.05518.817
Placebo17.16017.67518.12518.52519.631

Hamilton Depression Rating Scale-17 Item (HDRS) Total Score

Hamilton Depression Rating Scale-17 item (HDRS) is a scale that assesses depressive symptoms. HDRS consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher scores indicate more severe depression. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)15.93014.97515.47516.11216.74816.73217.73218.160
Placebo17.38917.73918.03917.33917.63919.28919.03919.438

Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.

Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)26.88125.38125.83526.51727.65429.16130.73231.447
Placebo28.61829.71829.81829.41829.11831.36830.36831.222

Scale for Suicide Ideation (SSI) Total Score.

Scale for Suicide Ideation (SSI) is a 19-item scale designed to quantify the intensity of current conscious suicide ideation. Each item is rated on a scale of 0 to 2 (with higher scores indicating greater suicidal ideation). The individual item scores are added together to form a total score, ranging between 0 and 38. 0 is considered the best outcome, 38 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)0.9551.1371.1370.8641.3641.2361.3791.379
Placebo0.9391.0390.9890.9391.5391.1891.2261.507

The Number of Participants With at Least 50% Reduction in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (MADRS Response).

Response defined as a >= 50% reduction from baseline in MADRS total score. MADRS is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionParticipants (Number)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)56443111
Placebo31010000

The Number of Participants With Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than 10 (MADRS Remission).

Remission defined as a Montgomery-Asberg Depression Rating Scale (MADRS) total score <10. MADRS is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionParticipants (Number)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)24422111
Placebo10000000

Visual Analogue Scale (VAS) Anxious Score.

"The Visual Analog Scale (VAS) Anxious is a 0 to 100-mm self-administered scale where patients rate their mood between extreme sad (0-mm) and extreme happy (100-mm), with a median normal point." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)43.89844.21642.85344.58044.98944.71842.62350.147
Placebo41.92944.07944.72946.02947.22950.47948.27956.595

Visual Analogue Scale (VAS) Depressed Score

"The Visual Analog Scale (VAS) Depressed is a 0 to 100-mm self-administered scale where patients rate their mood between extreme sad (0-mm) and extreme happy (100-mm), with a median normal point." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing

,
InterventionScores on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)55.61458.61460.75055.61462.16065.75366.89668.467
Placebo60.56257.66259.06261.21264.76263.26263.31265.576

Young Mania Rating Scale (YMRS) Score.

Young Mania Rating Scale (YMRS) consists of 11 items, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe) or from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. 0 is considered to be the best outcome, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.

,
InterventionUnits on a scale (Least Squares Mean)
60 minutes80 minutes110 minutes230 minutesDay 1Day 2Day 3Day 7
AZD6765 (150 mg)4.2943.7483.4753.7483.7483.6994.2704.366
Placebo3.6263.5263.5263.5263.3263.6763.4764.339

Trials

7 trials available for niacinamide and Depression

ArticleYear
Effect of Tryptophan, Vitamin B
    Journal of nutritional science and vitaminology, 2019, Volume: 65, Issue:6

    Topics: Adolescent; Adult; Affect; Depression; Dietary Supplements; Double-Blind Method; Female; Heart Rate;

2019
[Investigation of the effects of cytoflavin on symptoms of depression and autonomic dysfunction in patients with organic depressive disorder].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:12

    Topics: Adult; Antidepressive Agents; Autonomic Nervous System Diseases; Depression; Depressive Disorder; Dr

2013
Letter: Treatment of unipolar depression.
    Lancet (London, England), 1975, Sep-13, Volume: 2, Issue:7933

    Topics: Depression; Electroconvulsive Therapy; Female; Humans; Male; Middle Aged; Niacinamide; Tryptophan

1975
Tryptophan-nicotinamide combination in depression.
    Lancet (London, England), 1977, Jan-29, Volume: 1, Issue:8005

    Topics: Adult; Aged; Clinical Trials as Topic; Depression; Drug Synergism; Drug Therapy, Combination; Female

1977
Tryptophan dosage critical for its antidepressant effect.
    British medical journal, 1978, May-27, Volume: 1, Issue:6124

    Topics: Clinical Trials as Topic; Depression; Double-Blind Method; Drug Synergism; Humans; Imipramine; Niaci

1978
Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study.
    Acta psychiatrica Scandinavica, 1979, Volume: 59, Issue:4

    Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Evaluation;

1979
Long-term management of symptoms of cerebral arteriosclerosis.
    Geriatrics, 1971, Volume: 26, Issue:7

    Topics: Aged; Anxiety; Clinical Trials as Topic; Depression; Drug Synergism; Female; Humans; Intracranial Ar

1971

Other Studies

23 other studies available for niacinamide and Depression

ArticleYear
Cross-Sectional Associations between Dietary Daily Nicotinamide Intake and Patient-Reported Outcomes in Colorectal Cancer Survivors, 2 to 10 Years Post-Diagnosis.
    Nutrients, 2021, Oct-21, Volume: 13, Issue:11

    Topics: Aged; Anxiety; Cancer Survivors; Cognition; Colorectal Neoplasms; Cross-Sectional Studies; Depressio

2021
Antidepressant activity of crocin-I is associated with amelioration of neuroinflammation and attenuates oxidative damage induced by corticosterone in mice.
    Physiology & behavior, 2019, 12-01, Volume: 212

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Carotenoids; Corticosterone; Depression; Hippocamp

2019
Nicotinamide riboside alleviates alcohol-induced depression-like behaviours in C57BL/6J mice by altering the intestinal microbiota associated with microglial activation and BDNF expression.
    Food & function, 2020, Jan-29, Volume: 11, Issue:1

    Topics: Animals; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Disease Models, Animal; Ethanol;

2020
Nicotinamide, a vitamin B3 ameliorates depressive behaviors independent of SIRT1 activity in mice.
    Molecular brain, 2020, 11-23, Volume: 13, Issue:1

    Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Behavior, Animal; Depression; Integrases; Ma

2020
Antidepressant-like effects of 1-methylnicotinamide in a chronic unpredictable mild stress model of depression.
    Neuroscience letters, 2021, 01-18, Volume: 742

    Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Depression; Dise

2021
How gut microbes could drive brain disorders.
    Nature, 2021, Volume: 590, Issue:7844

    Topics: alpha-Synuclein; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder

2021
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
    British journal of pharmacology, 2013, Volume: 170, Issue:3

    Topics: Adenosine Triphosphate; Analgesics; Animals; Antidepressive Agents; Antimanic Agents; Behavior, Anim

2013
[Effect of cytoflavin on the clinical and autonomic-psychological manifestations of hypertensive disease].
    Terapevticheskii arkhiv, 2016, Volume: 88, Issue:5

    Topics: Adult; Aged; Antihypertensive Agents; Anxiety; Autonomic Nervous System Diseases; Cognition Disorder

2016
Ligand autoradiographical quantification of histamine H
    Pharmacological research, 2016, Volume: 113, Issue:Pt A

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autoradiography; Benzazepines; Cerebellar Cortex; Dement

2016
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum

2017
Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
    Histopathology, 2011, Volume: 59, Issue:3

    Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Tri

2011
Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats.
    Pharmacology, biochemistry, and behavior, 2004, Volume: 77, Issue:2

    Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri

2004
[Symmetrical bullous acral erythema in a 58-year-old female alcoholic].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2006, Volume: 57, Issue:11

    Topics: Administration, Oral; Alcoholism; Anti-Anxiety Agents; Biopsy; Depression; Diagnosis, Differential;

2006
Tryptophan in the treatment of depression.
    Advances in experimental medicine and biology, 1981, Volume: 133

    Topics: Allopurinol; Antidepressive Agents, Tricyclic; Ascorbic Acid; Bipolar Disorder; Depression; Electroc

1981
[Several indices of the methylation process in schizophrenic patients].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1977, Volume: 77, Issue:7

    Topics: Adult; Antipsychotic Agents; Automatism; Catechol O-Methyltransferase; Depression; Female; Hallucina

1977
Letter: Tryptophan plus a pyrrolase inhibitor for depression?
    Lancet (London, England), 1975, Jan-18, Volume: 1, Issue:7899

    Topics: Allopurinol; Brain; Depression; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Time

1975
Letter: Tryptophan plus a pyrrolase inhibitor for depression.
    Lancet (London, England), 1975, Nov-01, Volume: 2, Issue:7940

    Topics: Allopurinol; Animals; Depression; Drug Synergism; Drug Therapy, Combination; Glucose; Humans; Niacin

1975
N-methylnicotinamide excretion and affective disorders.
    Psychological medicine, 1976, Volume: 6, Issue:2

    Topics: Adjustment Disorders; Adolescent; Adult; Bipolar Disorder; Depression; Female; Humans; Male; Middle

1976
Tryptophan-nicotinamide combination in the treatment of newly admitted depressed patients.
    Communications in psychopharmacology, 1978, Volume: 2, Issue:4

    Topics: Adult; Bipolar Disorder; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; N

1978
Letter: Tryptophan plus a pyrrolase inhibitor for depression?
    Lancet (London, England), 1974, Nov-16, Volume: 2, Issue:7890

    Topics: Adult; Allopurinol; Animals; Depression; Drug Evaluation; Drug Synergism; Drug Therapy, Combination;

1974
[Psychopathology of pellagra in children].
    Psychiatrie, Neurologie, und medizinische Psychologie, 1971, Volume: 23, Issue:3

    Topics: Bipolar Disorder; Brain Damage, Chronic; Child; Depression; Electroencephalography; Hallucinations;

1971
The "kynurenine shunt" and depression.
    Advances in biochemical psychopharmacology, 1974, Volume: 11, Issue:0

    Topics: Adrenal Glands; Adrenalectomy; Amitriptyline; Animals; Antidepressive Agents; Depression; Humans; Im

1974
Letter: Suicide and depression in childhood and adolescence.
    Canadian Medical Association journal, 1974, Sep-07, Volume: 111, Issue:5

    Topics: Adolescent; Age Factors; Ascorbic Acid; Avitaminosis; Child; Depression; Humans; Niacinamide; Pellag

1974